Immunodeficient Mice
- Products
- Animal Models
- Immunodeficient Mice
- NOD-SCID
NOD-SCID
Strain Name: NOD/ShiLtJGpt-Prkdcem26Cd52/Gpt
Strain Type: Knockout (KO)
Strain Number: T001492
NOD-SCID mice are immunodeficient animals developed by knocking out the Prkdc gene on a NOD (Non-Obese Diabetic) background using CRISPR-Cas9 technology. The original NOD strain is known for spontaneously developing type 1 diabetes and carrying natural immune system defects, including weak complement activity, impaired macrophages, and low NK cell function. By removing Prkdc, NOD-SCID mice lose functional T and B cells, creating a model that combines both adaptive and innate immune deficiencies. Unlike traditional SCID mice, NOD-SCID mice also express a version of the SIRPα protein that binds strongly to human CD47, improving their ability to accept human cells and tissues.
Immune & Inflammation Research
Athymism Research
Xenograft & Cancer Research
Strain Name
NOD/ShiLtJGpt-Prkdcem26Cd52/Gpt
Strain Number
T001492
Official Symbol
Prkdc
Strain Strategy
Official Full Name
protein kinase,DNA activated,catalytic polypeptide
Also Known As
AI326420,AU019811,DNA-PKcs,DNAPDcs,DNAPK,DNPK1,DOXNPH,HYRC1,XRCC7,dxnph,p460,scid,slip
NCBI Number
MGI Number
Chromosome
16
Strain Background
[N000235] NOD/ShiLtJGpt
Modification Type
Knockout (KO)
Inventory Status
Live Animal, Cryopreserved
Health Status
Specific pathogen free (SPF)
Publications
1.USP7 deubiquitinates KRAS and promotes non-small cell lung cancer. Cell Rep (2024)
2.Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma. Theranostics (2025)
3.ICAT mediates the inhibition of stemness and tumorigenesis in acute myeloid leukemia cells induced by 1,25-(OH)2D3. Oncology research (2025)
4.TCL1A in naïve B cells as a therapeutic target for type 1 diabetes. EBioMedicine (2025)
5.TMEM45A enhances palbociclib resistance and cellular glycolysis by activating AKT/mTOR signaling pathway in HR+ breast cancer. Cell death discovery (2025)
6.Regulating chemoresistance and cancer stemness: the CDH17-YAP pathway in distinct cellular states of lung cancer CTC clusters. Cellular & molecular biology letters (2025)
7.The E3 ubiquitin ligase MAEA promotes macrophage phagocytosis and inhibits gastrointestinal cancer progression by mediating PARP1 ubiquitination and degradation. International journal of biological sciences (2025)
1. NOD-SCID Peripheral Blood Immune Cell Sub-population Statistics
Peripheral blood of 7-week-old NOD and NOD-SCID mice was taken for flow assay to determine the ratio of their immune cell fractions. The results showed that compared with NOD, there were almost no T and B cells in NOD-SCID, the proportion of NK cells increased compensatory, the proportion of DC cells, neutrophils, monocytes and eosinophils increased, and the proportion of macrophages decreased.
Figure 1. NOD, NOD-Scid and NCG mice statistical plot of the percentage of peripheral blood immune cell fractions (n=5)
2. NOD-SCID Spleen Immune Cell Sub-population Statistics
The spleens of 7-week-old NOD and NOD-SCID mice were taken for flow assay to determine their immune cell fraction ratios. The results showed that compared with NOD, NOD-SCID had almost no T and B cells, a compensatory increase in the proportion of NK cells, and an increase in the proportion of DC cells, neutrophils, monocytes, eosinophils
Figure 2. NOD, NOD-Scid and NCG mice statistical plot of the percentage of splenic immune cell fractions(n=5)
3. NOD-SCID Growth Curve
Body weight analysis was performed for 12-week-old NOD-SCID mice. The results showed that the body weight of NOD-SCID male mice was generally higher than that of female mice.
Figure 3. Growth curve of NOD-SCID mice
Axiocell Biotech Sdn Bhd.
Suite 2-5, Level 18, Plaza Azalea 10, Persiaran Bandaraya, Seksyen 14, 40000 Shah Alam, Selangor.
© 2025 AXIOCELL BIOTECH. All rights reserved.
Developed by Infinicore – Design by LeMoon